 RARITAN, N.J., Sept. 09, 2021 GLOBE NEWSWIRE -- Ortho Clinical Diagnostics Holdings plc Nasdaq: OCDX the Company, one of the worlds largest pure-play in vitro diagnostics companies, today announced the pricing of the previously announced underwritten secondary offering of 22,000,000 of the Companys ordinary shares held by a selling shareholder affiliated with The Carlyle Group the Selling Shareholder at a price of 17.50 per ordinary share. The offering is expected to close on September 14, 2021, subject to customary closing conditions. The Selling Shareholder granted the underwriters a 30-day option to purchase up to 3,300,000 additional ordinary shares of the Company at the public offering price less the underwriting discount. 